Navigation Links
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
Date:3/12/2008

w.cadencepharm.com" target="_new">http://www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Forward-looking Statements

Cadence cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. These forward-looking statements include statements regarding: the timeframes in which Cadence expects to initiate, complete enrollment in, and disclose results from its clinical trials of Acetavance and Omigard, and the timeframes for filing submissions with regulatory authorities seeking marketing authorizations for these product candidates; statements regarding the effects of management changes; Cadence's projected operating expenses and cash balances for 2008; and the adequacy of the company's funding to advance its product candidates through to NDA submissions. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Cadence's business, including, without limita
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
2. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
3. ISTA Pharmaceuticals to Present at the Cowen & Company 28th Annual Health Care Conference
4. SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results
5. Onyx Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
6. Idenix Pharmaceuticals to Present at the Eleventh Annual Lehman Brothers Global Healthcare Conference
7. Drinking Water Association Discusses Pharmaceuticals in Water
8. Genesis Pharmaceuticals Changes Auditors
9. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
10. Statement from American Water Works Association on Associated Press Story on Pharmaceuticals in Drinking Water
11. Vion Pharmaceuticals Regains NASDAQ Listing Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... a healthy lifestyle may help childhood cancer survivors reduce ... indicates. Researchers suggested that children with cancer and ... about how their diet and certain behaviors could ... are important because they indicate that adults who were ... influence their own health outcomes," said one of the ...
(Date:7/28/2014)... 28, 2014 Glidewell Laboratories announced today ... have successfully passed the five-year mark in clinical usage, ... million units prescribed by US dentists. , Even as ... with good results from respected clinical studies, many dentists ... perform over extended years of clinical service before they ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 This ... Global and Chinese Tadalafil industry. The report firstly ... classification, application and manufacturing technology. The report then ... listing their product specification, capacity, Production value, and ... quantitatively 2009-2014 global and China’s total market of ...
(Date:7/28/2014)... Raleigh, NC (PRWEB) July 28, 2014 ... they say is an improved blood test for the ... article on the new research. Click here to ... of Respiratory Medicine at Tokyo’s Juntendo University Graduate School ... biomarker called N-ER/mesothelin is a step above the old ...
(Date:7/28/2014)... July 28, 2014 Community Health Center ... medical, dental, and pharmacy services, has released an article ... chronic disease management . Founded in 1983, the health ... those of the county that face barriers to obtaining ... make an appointment at the CHC, click here: ...
Breaking Medicine News(10 mins):Health News:Healthy Habits May Help Childhood Cancer Survivors Avoid Chronic Ills 2Health News:BruxZir® Solid Zirconia Surpasses Five Years of Clinical Use 2Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 4Health News:Test Results Look Promising for New Mesothelioma Blood Test, According to Surviving Mesothelioma 2Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 2Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 3
... Youthful ... Appearance, BEVERLY HILLS, Calif., ... Hills, CA states,"Changing the size and shape of your teeth can significantly ... patients,say that a smile make-over is better than botox in restoring a ...
... Prime Therapeutics (Prime), a,thought leader in pharmacy ... joined the organization as Vice President of,Pharmacy Trade ... Relations, Wan will focus on,developing and maintaining relationships ... in the development of strategic pharmacy,contracts and the ...
... Corporation,(Nasdaq: DRAD ), a leading provider of ... hospitals and imaging centers, today,reported financial results for ... revenues were higher, compared to the same time ... imaging services revenues within Digirad,Imaging Solutions. The Company,s ...
... Group, Inc. (Phyhealth) (Pink Sheets: PHYH), a developer ... announced that Phyhealth Plan Corporation, a wholly-owned subsidiary,of ... to provide,comprehensive vision services for its Pilot HMO ... 2008., Mr. Robert Trinka, chairman and chief ...
... C-Change champions the Cancer Patient Navigation Act on ... sets into motion,a world of confusion and questions ... navigation services brings the patient-focus,back to cancer care ... a,skilled navigator guide him or her thought the ...
... ST. LOUIS, April 23 Young Innovations, Inc.,(Nasdaq: YDNT ... Sales for the first quarter of 2008 were $24.4 ... million reported in the first quarter,of 2007. Income from operations ... from $4.7 million in the first quarter of 2007. Net ...
Cached Medicine News:Health News:'Size Does Matter ... and So Does Shape ... When It Comes to Teeth,' Says Cosmetic Dentist, Dr. Denise Fundora 2Health News:Digirad Corporation Reports Financial Results for First-Quarter 2008 2Health News:Digirad Corporation Reports Financial Results for First-Quarter 2008 3Health News:Digirad Corporation Reports Financial Results for First-Quarter 2008 4Health News:Digirad Corporation Reports Financial Results for First-Quarter 2008 5Health News:Digirad Corporation Reports Financial Results for First-Quarter 2008 6Health News:Digirad Corporation Reports Financial Results for First-Quarter 2008 7Health News:Digirad Corporation Reports Financial Results for First-Quarter 2008 8Health News:Phyhealth Signs Agreement with Advantica EyeCare to Provide Vision Services for Pilot HMO 2Health News:Support for Patient Navigation Services to Help Cancer Patients 2Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2008 2Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2008 3Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2008 4Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2008 5
(Date:7/28/2014)... , Germany und ... , Ziel ... das auf Basis genomischer Daten aus Plasmaproben zur ... nicht-kleinzelligem Lungenkrebs eingesetzt werden kann  Neuer ... therascreen   EGFR Kit und soll auf Rotor-Gene Q, ...
(Date:7/25/2014)... N.C. , July 25, 2014  Corporate libraries ... including understanding new advancements in technology and how to ... this, libraries in the pharmaceutical and medical device industries ... of the information and services they provide. ... Practices, LLC there are many forces of change that ...
(Date:7/25/2014)... /PRNewswire-iReach/ -- ScriptPro, of Mission, Kansas ... Lake, Wisconsin , announce that they will ... agreement allowing ScriptPro to bring TCGRx adherence packaging ... United States . ScriptPro is a leading ... to retail and ambulatory pharmacies. TCGRx distributes and ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7Forces of Change Reshaping Corporate Libraries & Information Services 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3
... in bone mineral density at the,lumbar spine and ... salmeterol inhalation powder) and salmeterol, - Study ... in patients,with COPD, PHILADELPHIA, Oct. 29 ... three-year study of patients with,Chronic Obstructive Pulmonary Disease ...
... Cryoablation ... Treatment Technology, PLEASANTON, ... (ACOSOG) which just initiated a National Cancer,Institute (NCI) funded clinical ... Therapy in the Treatment of Invasive Breast,Carcinoma," has selected the ...
Cached Medicine Technology:Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD 2Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD 3NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 2NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 3
The Advia 60 is designed to deliver powerful performance in a small package....
... three-dimensional VCS technology, providing ... efficiency in white cell ... With its reputation for ... is an affordable solution ...
Creatinine Test Kit (enzymatic), Wavelength: 340 nm. Linear range: up to 20 mg/dL....
For the quantitative determination of Creatine Kinase in serum....
Medicine Products: